Anthem BCBS to Cover XDx's AlloMap in Stable Heart Transplant Patients

"AlloMap molecular expression testing is considered medically necessary as a non-invasive method of determining the risk of rejection in heart transplant recipients between one and five years post transplant," Anthem wrote in an updated medical policy.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.